This paper is in the following e-collection/theme issue:

RCTs - Protocols/Proposals (funded, already peer-reviewed, non-eHealth) (173)

Published on in Vol 9, No 4 (2020): April

Efficacy and Safety of Rituximab in Refractory CIDP With or Without IgG4 Autoantibodies (RECIPE): Protocol for a Double-Blind, Randomized, Placebo-Controlled Clinical Trial

Efficacy and Safety of Rituximab in Refractory CIDP With or Without IgG4 Autoantibodies (RECIPE): Protocol for a Double-Blind, Randomized, Placebo-Controlled Clinical Trial

Efficacy and Safety of Rituximab in Refractory CIDP With or Without IgG4 Autoantibodies (RECIPE): Protocol for a Double-Blind, Randomized, Placebo-Controlled Clinical Trial

Authors of this article:

Shinobu Shimizu1 Author Orcid Image ;   Masahiro Iijima1, 2 Author Orcid Image ;   Yuki Fukami2 Author Orcid Image ;   Natsuko Tamura1, 3 Author Orcid Image ;   Masahiro Nakatochi1, 4 Author Orcid Image ;   Masahiko Ando1 Author Orcid Image ;   Ryoji Nishi2 Author Orcid Image ;   Haruki Koike2 Author Orcid Image ;   Kenichi Kaida5 Author Orcid Image ;   Michiaki Koga6 Author Orcid Image ;   Takashi Kanda6 Author Orcid Image ;   Hidenori Ogata7 Author Orcid Image ;   Jun-Ichi Kira7 Author Orcid Image ;   Masahiro Mori8 Author Orcid Image ;   Satoshi Kuwabara8 Author Orcid Image ;   Masahisa Katsuno2 Author Orcid Image
Article Authors Cited by (26) Tweetations (2) Metrics
All Time | Last Month | Last Six Months | Last Year
There are currently no tweets available for this article within the specified range.